No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Inner Mongolia Furui Medical Science Co., Ltd. functions as a dedicated platform offering specialized healthcare services. The company's primary focus lies in the liver disease sector, where it delivers a full spectrum of solutions encompassing accurate disease diagnosis, pharmaceutical treatments, and ongoing chronic condition management. Beyond this, it also provides comprehensive health management facilities and general medical care services. Established in 1998, with its headquarters situated in Beijing, China, the entity was previously known as Inner Mongolia FuRui Pharmaceutical Limited Liability Company.
www.fu-rui.comNo one on the platform currently holds 300049.SZ.
No tracked institution reports a position in 300049.SZ as of their last filing.
No one on the platform has traded 300049.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.1% | 13.8% | 11.3% | — | — | — |
| Rev. Growth % | 18.1% | 14.6% | ||||
| Profit Margin % | 9.7% | 9.4% | 8.6% | |||
| Free Cash Flow Margin % | 10.4% | 8.9% | 8.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.0B | +28.2% | $0.90 | $0.87–$0.93 | — | 1 |
| 2027 | $2.5B | +25.3% | $1.20 | $1.16–$1.24 | — | 1 |
| 2028 | $3.2B | +25.4% | $1.60 | $1.54–$1.65 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300049.SZInner Mongolia Furui Medical Science Co., Ltd. | $48.21 | +0.61% | $12.7B | — |
| 300009.SZAnhui Anke Biotechnology (Group) Co., Ltd. | $7.95 | -0.13% | $13.3B | — |
| 300204.SZStaidson (Beijing) BioPharmaceuticals Co., Ltd. | $19.43 | -0.15% | $8.8B | — |
| 300253.SZWinning Health Technology Group Co., Ltd. | $6.58 | -0.45% | $14.5B | — |
| 300573.SZShenyang Xingqi Pharmaceutical Co.,Ltd | $36.20 | +0.28% | $12.9B | — |
| 300957.SZYunnan Botanee Bio-Technology Group Co.LTD | $31.25 | +0.42% | $13.2B | — |
| 600062.SSChina Resources Double-Crane Pharmaceutical Co.,Ltd. | $15.81 | -1.06% | $16.4B | — |
Source: Financial Modeling Prep · peers by sector/industry